# Canton Strategic Holdings, Inc. (CNTN) — divestiture/joint_venture [completed]
Source: SEC API (secapi.ai) · situation sit_45991c69e4a5f1c072aa · retrieved 2026-08-11T16:11:25.720Z

## Overview
Canton Strategic Holdings, Inc. is a publicly traded company that leverages Canton Coin to support the Canton Network's ability to digitize traditional financial markets; it was divesting its biotech research and development arm, Gravitas Life Sciences, which develops therapeutic candidates for immunology and inflammation conditions.

Canton Strategic Holdings, Inc. sold all membership interests of its subsidiary Gravitas Life Sciences, LLC to Gravitas Collective Corp. on July 17, 2026. Gravitas operates clinical-stage biotech research and development developing therapeutic candidates for immunology and inflammation conditions. As consideration, Buyer and Gravitas issued an unsecured promissory note with an original principal amount of $3,500,000 bearing interest at 15% per annum, payable in kind and compounding semi-annually, with a maturity date of July 17, 2029. The Buyer is affiliated with former directors of Canton Strategic. Certain assets of Gravitas relating to bispecific antibodies development were retained by Canton through its subsidiary Tharimmune SPV1.

## Terms
- Counterparty: Gravitas Collective Corp. · Deal value: $3.5M · Consideration: mixed · Stake: 100%

## Key dates
- Completed 2026-07-17

## Timeline
- 2026-07-23 · 8-K (0001493152-26-034340): 8-K - Canton Strategic Holdings, Inc. — *Canton Strategic Holdings, Inc. is a publicly traded company that leverages Canton Coin to support the Canton Network's ability to digitize traditional financial markets; it was divesting its biotech research and development arm, Gravitas Life Sciences, which develops therapeutic candidates for immunology and inflammation conditions.* Canton Strategic Holdings, Inc. sold all membership interests of its subsidiary Gravitas Life Sciences, LLC to Gravitas Collective Corp. on July 17, 2026. Gravitas operates clinical-stage biotech research and development developing therapeutic candidates for immunology and inflammation conditions. As consideration, Buyer and Gravitas issued an unsecured promissory note with an original principal amount of $3,500,000 bearing interest at 15% per annum, payable in kind and compounding semi-annually, with a maturity date of July 17, 2029. The Buyer is affiliated with former directors of Canton Strategic. Certain assets of Gravitas relating to bispecific antibodies development were retained by Canton through its subsidiary Tharimmune SPV1.
  https://www.sec.gov/Archives/edgar/data/1861657/0001493152-26-034340.txt

## Citations
- 0001493152-26-034340 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226034340